Biofidelity and CellCarta have announced a strategic partnership to utilise Biofidelity’s Aspyre® Lung in global clinical ...

Cambridge Cognition Holdings plc has expanded its partnership with Actinogen Medical Limited for the phase 2b/3 XanaMIA Alzheimer’s disease trial. Building on the successful integration of Cambridge ...

Owlstone Medical has announced a first close of $27 million (circa £22 million) in its Series E financing round. The round ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...

Groundbreaking approval provides new hope for patients in England and Wales The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...

Prostate cancer resistant to hormone therapy could soon have a new treatment option. The Institute of Cancer Research (ICR), London, found that the drug NXP800, currently in trials for ovarian and ...

Cambridge Cognition has praised Bristol Myers Squibb for the FDA approval of Cobenfy (KarXT), a new treatment for schizophrenia. Recent research published in The American Journal of Psychiatry ...

Investment to support RNA therapeutics for epilepsy and neurological disorders Angelini Ventures has co-led a €20 million Series A financing round in Neumirna Therapeutics. The financing, also led by ...